Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP 215 versus bevacizumab in advanced non-squamous non-small cell lung cancer
NL-OMON40174Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Nov 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bevacizumab-bvzr in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Amgen. Primary endpoint: Overall response rate risk ratio. Started Nov 2013; status: active, not recruiting.
02
Drugs
bevacizumab-bvzr
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON40174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40174.